Summary
A welsh company and an American one are teaming up to develop a tool which will allow doctors to swiftly screen for the most common cause of genetic liver disease in children. BBI (British Biocell International) announced yesterday that it had signed an agreement with Talecris Biotherapeutics to develop the technology.
Alpha-1 is an inherited disorder which causes significant reduction in the naturally occurring protein AAT. As well as making children susceptible to liver disease, it is the leading cause of genetic emphysema (shortness of breath) in adults.See the full content of this document
Extract
Bbi Teams Up with Us Ally to Develop Liver Screening Tool
It is most common in the Caucasian population of Northern Europe and North America, where it affects around 150,000.
Scientists at Cardif...See the full content of this document
Sponsored links
